Asklepios BioPharmaceutical, Inc. (AskBio)’s Post

Cell and Gene Therapies (CGTs) are changing the face of medicine, bringing hope where there was none. But their potential comes with challenges. They can be complex, expensive, and time-consuming to develop. Imagine if we could simplify this path.   Our goal is clear: to efficiently bring life-altering therapies to those who need them the most. Discover how we are reshaping the CGT landscape: https://lnkd.in/d3cH5dUt

Top 10 Best-Selling Cell and Gene Therapies Ranking cell and gene therapies in terms of revenues shows a fairly stark line between feast and famine. The feast side is well covered in this A-List, which ranks the top 10 therapies according to sales figures from 2023. The famine side begins almost exactly where this A-List ends, but future A-Lists are bound to push famine farther into the background. For more A-Lists by Alex Philippidis visit https://ow.ly/Frza50RypIi

After obtaining the big data from mapping individualized immune response differences, Cell and and Gene therapy , as well as personalized medicine will the stars of the future. Here is a great article to read: https://lnkd.in/ds8zNth3

This should be interesting.

Fierce Pharma quotes Sulayman P., MSci, pharma analyst at #globaldata regarding the potential of gene therapies in the treatment of #gaucherdisease: "Key opinion leaders interviewed by GlobalData have emphasized the promise of gene therapy, identifying these treatments as game-changers for the future of Gaucher disease management."... "While in preliminary stages, these offer a paradigm shift from existing treatments, which offer no resolution for neurological manifestations. Indeed, our experts have highlighted the need for more safety data. However, this will be explored as we await further developments." #DecodeTheFuture with GlobalData Plc #healthcare #GlobalDataHealthcare #GlobalDataInsights #GaucherDisease Tina Taylor PS Sarath Chandra

According to Rare Disease Advisor, “2024 will be a breakout year in addressing key challenges to developing cell and gene therapies, especially for rare disorders.”   Sadly, science continues to outpace the commercialization of innovative therapies while the pharmaceutical industry remains slow to change. As a result, patients are getting lost in the shuffle. At MPATHIK, we’re tackling these shifts head-on with empathy and collaboration.   Learn more about what’s expected in 2024 for gene therapies: https://lnkd.in/eWPSz2Jk

Read More: https://lnkd.in/ggyek-Wm #Cell & #GeneTherapyManufacturing Services Industry is projected to witness a CAGR of 19.9% from 2023 to 2032. This growth can be attributed to the increasing grants and investments for developing cell and gene therapies.

✨️ This meeting will be a informative gathering to hear a real voice and their meaningful consideration when they or their caregiver considers or decides to participate. As I a trsearcher and project manager to manage the project, kinds of those initiatives or approaches are very helpful to improve all. #Clinicaltrial #CRO #CNRRESEARCH #FDA #Genetherapy #longtermstudy #임상시험 #연장연구 #씨엔알리서치

Gene therapy is currently far from perfect, and one of the main concerns remains the safety of using these treatments. Patients who have undergone gene therapy often face autoimmune reactions, toxicity, and other adverse effects. I think the open FDA webinar, which you can register for, will provide a lot of new information and allow for discussion of key safety issues in gene therapy. I'm going!

#Cell & #GeneTherapy Manufacturing Services Industry is projected to witness a CAGR of 19.9% during the period 2023-2032. This growth can be attributed to the increasing grants and investments for the development of cell and gene therapies.